ArticleEuropean heart journal. Case reports2026
Efficacy of ranolazine in reducing complex premature ventricular contractions in a patient with mitral valve prolapse: a case report.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pharmacological options for treating arrhythmic mitral valve prolapse (aMVP) are limited and anecdotal. Ranolazine as an antiarrhythmic has yielded satisfactory outcomes in suppressing ventricular arrhythmias, but its role in the case of aMVP is unknown. Case summary: A 62-year-old female presented complaining of palpitations. ECG and the cardiac monitor showed very frequent and complex monomorphic premature ventricular contractions (PVCs), likely from the posteromedial papillary muscle. Cardiac MRI revealed the presence of mitral valve prolapse. Empirical treatment with ranolazine 1000 mg b.i.d. was initiated for antiarrhythmic purposes, with subjective clinical improvement and objective reduction of complex PVCs after 32 months of follow-up. Discussion: Papillary muscle PVCs are a common finding in patients with aMVP. Antiarrhythmic properties of ranolazine can be safely used in patients with contraindications to other interventions for the treatment of PVCs associated with mitral valve prolapse. The effect seems more evident on complex PVCs and ventricular tachycardia and can be attributed to an intrinsic use dependence of the drug; therefore, this treatment should be explored for selected cases. To the best of our knowledge, this is the first report of a case of improvement in PVCs following the administration of a high dose of ranolazine in a patient with aMVP. Future investigations on a larger scale should focus on whether ranolazine can be safely used as an alternative treatment to reduce the risks of ventricular arrhythmia and improve patients' prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.